Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent
1980-06-14
1982-02-23
Phillips, Delbert R.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reduced antigenicity, reduced ability to bind complement, or...
2601125S, A61K 3700, C07C10352
Patent
active
043168914
ABSTRACT:
28-member residue and 25-member residue peptides have been synthesized containing the tetradecapeptide somatostatin that are more potent than somatostatin. Somatostatin-28 has the formula: ##STR1## The three N-terminal amino acid residues are absent in somatostatin-25. Somatostatin-28 or somatostatin-25 or a pharmaceutically acceptable addition salt thereof, dispersed in a pharmaceutically acceptable liquid or solid carrier, can be administered to mammals in the same manner as somatostatin.
REFERENCES:
patent: 3904594 (1975-09-01), Guillamin et al.
patent: 3931140 (1976-01-01), Sarantakis
patent: 3998795 (1976-12-01), Sarantakis
patent: 4055553 (1977-10-01), Chai et al.
patent: 4093609 (1978-06-01), Sarantakis
J. Endocr. (1978) 77, 429-430.
Biochem. and Biophys. Res. Communications 85, (1978) 701-708.
Bohlen Peter
Brazeau, Jr. Paul E.
Esch Fred S.
Guillemin Roger C. L.
Ling Nicholas C.
Phillips Delbert R.
The Salk Institute for Biological Studies
LandOfFree
Extended N-terminal somatostatin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Extended N-terminal somatostatin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extended N-terminal somatostatin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1774157